Literature DB >> 30651372

The Germline Variants rs61757955 and rs34988193 Are Predictive of Survival in Lower Grade Glioma Patients.

Ajay Chatrath1, Manjari Kiran1, Pankaj Kumar1, Aakrosh Ratan2, Anindya Dutta3.   

Abstract

Lower grade gliomas are invasive brain tumors that are difficult to completely resect neurosurgically. They often recur following resection and progress, resulting in death. Although previous studies have shown that specific germline variants increase the risk of tumor formation, no previous study has screened many germline variants to identify variants predictive of survival in patients with glioma. In this study, we present an approach to identify the small fraction of prognostic germline variants from the pool of over four million variants that we variant called in The Cancer Genome Atlas whole-exome sequencing and RNA sequencing datasets. We identified two germline variants that are predictive of poor patient outcomes by Cox regression, controlling for eleven covariates. rs61757955 is a germline variant found in the 3' UTR of GRB2 associated with increased KRAS signaling, CIC mutations, and 1p/19q codeletion. rs34988193 is a germline variant found in the tumor suppressor gene ANKDD1a that causes an amino acid change from lysine to glutamate. This variant was found to be predictive of poor prognosis in two independent lower grade glioma datasets and is predicted to be within the top 0.06% of deleterious mutations across the human genome. The wild-type residue is conserved in all 22 other species with a homologous protein. IMPLICATIONS: This is the first study presenting an approach to screening many germline variants to identify variants predictive of survival and our application of this methodology revealed the germline variants rs61757955 and rs34988193 as being predictive of survival in patients with lower grade glioma. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30651372      PMCID: PMC6497557          DOI: 10.1158/1541-7786.MCR-18-0996

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

2.  Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.

Authors:  Beth Dudley; Eve Karloski; Federico A Monzon; Aatur D Singhi; Stephen E Lincoln; Nathan Bahary; Randall E Brand
Journal:  Cancer       Date:  2018-01-23       Impact factor: 6.860

3.  Mutations in TRPV4 cause an inherited arthropathy of hands and feet.

Authors:  Shireen R Lamandé; Yuan Yuan; Irma L Gresshoff; Lynn Rowley; Daniele Belluoccio; Kumara Kaluarachchi; Christopher B Little; Elke Botzenhart; Klaus Zerres; David J Amor; William G Cole; Ravi Savarirayan; Peter McIntyre; John F Bateman
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

4.  Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.

Authors:  Wei Yan; Wei Zhang; Gan You; Junxia Zhang; Lei Han; Zhaoshi Bao; Yongzhi Wang; Yanwei Liu; Chuanlu Jiang; Chunsheng Kang; Yongping You; Tao Jiang
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

5.  REPURPOSING GERMLINE EXOMES OF THE CANCER GENOME ATLAS DEMANDS A CAUTIOUS APPROACH AND SAMPLE-SPECIFIC VARIANT FILTERING.

Authors:  Amanda Koire; Panagiotis Katsonis; Olivier Lichtarge
Journal:  Pac Symp Biocomput       Date:  2016

Review 6.  Using germline genomics to individualize pediatric cancer treatments.

Authors:  Navin Pinto; Susan L Cohn; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

7.  Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.

Authors:  Guan Zhen Yu; Ying Chen; Jie Jun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-01       Impact factor: 4.553

8.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

9.  RADAR: a rigorously annotated database of A-to-I RNA editing.

Authors:  Gokul Ramaswami; Jin Billy Li
Journal:  Nucleic Acids Res       Date:  2013-10-25       Impact factor: 16.971

10.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.

Authors:  Zhongwu Lai; Aleksandra Markovets; Miika Ahdesmaki; Brad Chapman; Oliver Hofmann; Robert McEwen; Justin Johnson; Brian Dougherty; J Carl Barrett; Jonathan R Dry
Journal:  Nucleic Acids Res       Date:  2016-04-07       Impact factor: 16.971

View more
  5 in total

1.  Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes.

Authors:  Brittany N Chao; Danielle M Carrick; Kelly K Filipski; Stefanie A Nelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-03-01       Impact factor: 4.090

2.  Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy.

Authors:  Ajay Chatrath; Aakrosh Ratan; Anindya Dutta
Journal:  iScience       Date:  2021-03-04

3.  Integrated bioinformatic pipeline using whole-exome and RNAseq data to identify germline variants correlated with cancer.

Authors:  Divya Sahu; Ajay Chatrath; Aakrosh Ratan; Anindya Dutta
Journal:  STAR Protoc       Date:  2022-04-04

Review 4.  Germline Variants That Affect Tumor Progression.

Authors:  Ajay Chatrath; Aakrosh Ratan; Anindya Dutta
Journal:  Trends Genet       Date:  2020-11-14       Impact factor: 11.639

5.  The pan-cancer landscape of prognostic germline variants in 10,582 patients.

Authors:  Ajay Chatrath; Roza Przanowska; Shashi Kiran; Zhangli Su; Shekhar Saha; Briana Wilson; Takaaki Tsunematsu; Ji-Hye Ahn; Kyung Yong Lee; Teressa Paulsen; Ewelina Sobierajska; Manjari Kiran; Xiwei Tang; Tianxi Li; Pankaj Kumar; Aakrosh Ratan; Anindya Dutta
Journal:  Genome Med       Date:  2020-02-17       Impact factor: 11.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.